Z-WEHD-FMK: Irreversible Caspase-5 Inhibitor for Inflammation and Apoptosis Research

Executive Summary: Z-WEHD-FMK (CAS 210345-00-9) is a cell-permeable, irreversible peptide inhibitor that selectively targets inflammatory caspases (caspase-1, -4, -5) and blocks proteolytic cleavage events central to inflammation and apoptosis (APExBIO). It is widely employed to dissect caspase signaling in cell biology and infectious disease models (Padia et al., 2025). The inhibitor prevents Chlamydia-induced Golgi fragmentation by blocking golgin-84 cleavage, decreasing bacterial proliferation and altering lipid trafficking (Z-WEHD-FMK Internal Resource). Z-WEHD-FMK is insoluble in water but dissolves readily in DMSO (≥46.33 mg/mL) or ethanol (≥26.32 mg/mL, ultrasonic assistance). Optimal conditions involve 80 μM treatment of infected HeLa cells for 9 hours, yielding a ~2 log reduction in bacterial counts. Storage at -20°C is advised; long-term solution stability is limited.

Biological Rationale

Inflammatory caspases are critical mediators in the host response to infection and tissue injury. Caspase-1, -4, and -5 are key effectors of both canonical and non-canonical inflammasome pathways, responsible for processing pro-inflammatory cytokines and driving pyroptosis (Padia et al., 2025). Dysregulation of these enzymes is implicated in infectious diseases, cancer, and immune disorders. Tools such as Z-WEHD-FMK, a tetrapeptide fluoromethyl ketone (FMK) derivative, allow researchers to dissect the specific contributions of inflammatory caspases in physiological and pathological contexts (related article—this article extends prior work by detailing actionable workflows and specificity boundaries).

Mechanism of Action of Z-WEHD-FMK

Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) is a synthetic peptide analogous to endogenous caspase substrates, modified with an irreversible FMK group at the C-terminus. Upon cell entry, Z-WEHD-FMK covalently binds to the active site cysteine in caspase-1, -4, and -5, irreversibly blocking their proteolytic activity (Padia et al., 2025). This prevents cleavage of downstream substrates such as golgin-84, halting inflammation-associated cellular remodeling and pyroptosis. The inhibitor is not hydrolyzed by other proteases under standard conditions, conferring selectivity. Cellular effects are dose- and time-dependent, with optimized inhibition observed at 80 μM for 9 hours in HeLa cells infected with Chlamydia trachomatis (see also: extended mechanism review—this article clarifies quantitative benchmarks).

Evidence & Benchmarks

• Z-WEHD-FMK irreversibly inhibits caspase-1, -4, and -5 enzymatic activity in vitro and in cell-based assays (Padia et al., 2025).
• In HeLa cells infected with C. trachomatis, 80 μM Z-WEHD-FMK for 9 hours blocks golgin-84 cleavage and reduces bacterial inclusion-forming units by approximately 2 logs (internal benchmark).
• The compound is insoluble in water but dissolves in DMSO (≥46.33 mg/mL) and ethanol (≥26.32 mg/mL with ultrasonic assistance); solutions are unstable long-term and should be freshly prepared (APExBIO).
• Specificity for inflammatory caspases allows selective inhibition of pyroptotic cell death, as shown in NSCLC models where caspase-1 activity is blocked (Padia et al., 2025, Fig. 2).
• Z-WEHD-FMK does not inhibit non-caspase proteases or canonical apoptosis effectors (e.g., caspase-3) at standard concentrations (protocol resource).

Applications, Limits & Misconceptions

Z-WEHD-FMK is used to dissect caspase-dependent inflammation, pyroptosis, and apoptosis in cell biology, infectious disease, and cancer research. It is particularly valuable for:

• Blocking caspase-1/4/5-mediated cleavage of substrate proteins during infection, as in Chlamydia pathogenesis models.
• Studying the role of inflammatory caspases in pyroptotic cell death in cancer and immune cells.
• Elucidating caspase-regulated lipid trafficking and organelle remodeling.

For broader protocol guidance and troubleshooting, see this article (this current page provides additional details on compound handling and result interpretation).

Common Pitfalls or Misconceptions

• Not effective against non-caspase proteases: Z-WEHD-FMK is highly selective and does not inhibit serine or metalloproteases.
• No effect on canonical apoptosis effectors: At standard doses, caspase-3 and -7 are minimally affected.
• Irreversible binding cannot be reversed by washing: Once bound, the inhibitor cannot be removed from the target enzyme.
• Long-term storage of solutions reduces potency: Prepare fresh solutions for each experiment; avoid repeated freeze-thaw cycles.
• Solubility limitations: The compound is insoluble in water; improper vehicle use reduces efficacy.

Workflow Integration & Parameters

Optimal use of Z-WEHD-FMK (APExBIO SKU A1924) in cell-based assays involves precise control of concentration, solvent, and timing:

• Stock solution preparation: Dissolve in DMSO (≥46.33 mg/mL) or ethanol (≥26.32 mg/mL, ultrasonic assistance).
• Storage: Maintain at -20°C; avoid prolonged storage of working solutions.
• Experimental benchmarks: For C. trachomatis-infected HeLa cells, use 80 μM final concentration for 9 hours at 37°C to block golgin-84 cleavage effectively (internal protocol).
• Controls: Always include vehicle-only and positive control caspase inhibitors for specificity assessment.
• Readouts: Monitor by immunoblotting for substrate cleavage (e.g., golgin-84) and by colony-forming unit (CFU) reduction for bacterial models.

For advanced troubleshooting and inter-assay reproducibility, refer to this resource (the present article extends its scope by detailing compound specificity and workflow parameters).

Conclusion & Outlook

Z-WEHD-FMK is a robust, well-characterized tool for dissecting inflammatory caspase signaling in diverse biological contexts. Its irreversible, selective inhibition of caspase-1, -4, and -5 underpins applications in inflammation, apoptosis, and infectious disease research. For detailed product and protocol information, see the Z-WEHD-FMK product page at APExBIO. Future advances may focus on expanding application domains, optimizing delivery, and elucidating context-dependent off-target effects.